WATERTOWN, Mass--VI Technologies (VITEX) has announced the appointment of Joseph M. Limber to its Board of Directors.
Limber, currently the president and CEO of ACLARA BioSciences, Inc., has 25 years of biotechnology and pharmaceutical management experience.
VITEX is a biotechnology company responsible for developing products that inactive and remove pathogens in blood. Using nucleic acid chemistry, the company produced Inactine Pathogen Inactivation. The technology inactivates blood-borne viruses and bacteria and is in Phase II of clinical trials.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.